J-Pharma drives first cancer LAT1 to phase III study with FDA nod

J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat (JPH‐203), in a global phase III Beacon-BTC study of biliary tract cancer following U.S. FDA alignment.